SCHEMBL4968757

SCHEMBL4968757

CCCCOC(=O)N1CC(CO)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
GBA2 Q9HCG7 1/20 0.48
ALDH1A1 P00352 2/20 0.42
NR1H2 P55055 1/20 0.41
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
ATM Q13315 1/20 0.40
TSHR P16473 2/20 0.38
HPGD P15428 2/20 0.38
HRH2 P25021 1/20 0.37
HRH1 P35367 1/20 0.37
BCHE P06276 1/20 0.37
HCAR2 Q8TDS4 1/20 0.36
NAAA Q02083 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
S1PR1 P21453 1/20 0.34
S1PR5 Q9H228 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724467 0.87 LMNA (0.51) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL9285131 0.87 LMNA (0.51) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL29655416 0.87 LMNA (0.50) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL4968751 0.86 LMNA (0.53) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL30129902 0.85 LMNA (0.51) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL30129908 0.85 LMNA (0.51) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL29812927 0.85 SMN1; SMN2 (0.49) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL4599962 0.85 SMN1; SMN2 (0.49) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL29813031 0.84 SMN1; SMN2 (0.48) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL725320 0.83 LMNA (0.58) LMNAPOLBSMN1; SMN2GBA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2754653-B1 AZETIDINE DERIVATIVE AND ANTIDEPRESSANT COMPOSITION CONTAINING SAME KOREA INST SCI & TECH (KR) 2016-11-09 EP disclosed
US-9120771-B2 Azetidine derivative and antidepressant composition including the same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2015-09-01 US disclosed
US-20140171402-A1 AZETIDINE DERIVATIVE AND ANTIDEPRESSANT COMPOSITION INCLUDING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2014-06-19 US disclosed
EP-1966159-A2 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2008-09-10 EP disclosed
WO-2007071963-A2 QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS ASTRAZENECA AB (SE) 2007-06-28 WO disclosed
EP-1644334-A1 ANTITHROMBOTIC ETHERS Eli Lilly and Company (US) 2006-04-12 EP disclosed
WO-2004108677-A1 ANTITHROMBOTIC ETHERS ELI LILLY AND COMPANY (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171402-A1 AZETIDINE DERIVATIVE AND ANTIDEPRESSANT COMPOSITION INCLUDING THE SAME SLC6A2, SLC6A3, SLC6A4 LMNA 4075/4885POLB 3666/4885SMN1; SMN2 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.